Anti-IL-6 receptor antibody (tocilizumab): A B cell targeting therapy

Clinical and Experimental Rheumatology

Volumn 29, Issue 4, 2011, Pages 697-700

  Snir, Ayelet ^a   Kessel, Aharon ^a   Haj, Tharwat ^a   Rosner, Itzhak ^a   Slobodin, Gleb ^a   Toubi, Elias ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

B cells; IL 6; Rheumatoid arthritis; TGF ; Tocilizumab

Indexed keywords

CD69 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; PREDNISONE; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; HLA ANTIGEN CLASS 2; IL10 PROTEIN, HUMAN; IL2RA PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR; LECTIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; T LYMPHOCYTE ANTIGEN;

ADD ON THERAPY; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; IMMUNOPHENOTYPING; ISRAEL; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; TIME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CELL PROLIFERATION; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISRAEL; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; RECEPTORS, INTERLEUKIN-6; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 80055093209     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Fonseca JE, Santos MJ, Canhao H, Choy E: Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538-42.
2. Mima T, Nishimoto N: Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009; 21: 224-30.
3. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY: Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006; 119:296-305.
4. Zhang R, Xing M, Ji X et al.: Interferonalpha and interleukin-6 in SLE serum induce the differentiation and maturation of dendritic cells derived from CD34+hematopoietic precursor cells. Cytokine 2010; 50: 195-203.
5. Kimura A, Kishimoto T: IL-6: Regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830-1835.
6. Ding C, Cicuttini F, LI J, Jones G: Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin Investig Drugs 2009; 18: 1457-1466.
7. Oldfield V, Dhillon S, Flosker GL: Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009; 69:609-632.
8. Nam JL, Winthrop KL, Van Vollenhoven RF et al.: Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systemic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-986.
9. Amu S, Tarkowski A, Dorner T, Bokarewa M, Brisslert M: The human immunomodulatory CD25+ B cell population belongs to the memory B cell pool. Scand J Immunol 2007; 66: 77-86.
10. Smolen JS, Aletaha D: The assessment of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28 (Suppl. 59): S18-S27.
11. Mihara M, Kasutani K, Okazaki M et al.: Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005; 5: 1731-40.
12. Dovio A, Masera RG, Sartori ML, Racca S, Angeli A: Autocrine up-regulation of glucocorticoid receptors by interleukin-6 in human osteoblast-like cells. Calcif Tissue Int 2001; 69: 293-8.
13. Yang M, Sun L, Wang S et al.: Cutting edge: Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol 2010; 184: 3321-25.
14. Toubi E, Kessel A, Slobodin G et al.: Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 818-20.
15. Dunn-Walters DK, Ademoyun AA: B cell repertoire and aging. Curr Opin Immunol 2010; 22: 514-20.
16. hi B cells exhibit regulatory capacity in Healthy individuals but are functionally impaired in systemic lupus erythematosus. Immunity 2010; 32: 129-40.
17. + expressing B cells. J Rheumatol 2010; 37: 2086-95.
18. Harp CT, Lovett-Racke AE, Racke MK, Frohman EM, Monson NL: Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol 2008; 128: 382-91.